Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of neutrophil-to Lymphocyte Ratio in Preeclampsia- Eclampsia

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor:
Information provided by (Responsible Party):
Ayse Kirbas, Zekai Tahir Burak Maternity and Teaching Hospital
ClinicalTrials.gov Identifier:
NCT01856387
First received: May 4, 2013
Last updated: March 16, 2014
Last verified: May 2013
  Purpose

Neutrophil/lymphocyte ratio (NLR) is a marker of systemic inflammation and endothelial dysfunction. In recent years, it has been reported that the individual components of the differential white cell count, specifically the neutrophil and lymphocyte counts,may have clinical utility in predicting diseases. An elevated NLR has been shown to be a prognostic indicator in various malignancies. İn the literature, many studies have been shown that NLR have predictive value in determining the prognosis of various diseases (cardiac or noncardiac diseases ). However, little is known about the predictive values of NLR in pregnancy complications. This study aimed to evaluate the potential predictive value of NLR in preeclampsia- eclampsia.


Condition Intervention
Preeclampsia
Eclampsia
Biological: high neutrophil to lymphocyte ratio
Other: normal neutrophil-to Lymphocyte ratio

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: the Predictive Value of neutrophil-to Lymphocyte Ratio on Preeclampsia- Eclampsia

Resource links provided by NLM:


Further study details as provided by Zekai Tahir Burak Women's Health Research and Education Hospital:

Primary Outcome Measures:
  • the effect of neutrophil lymphocyte ratio in preeclampsia eclampsia [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
    during 6 months ,the patients who was recorded with preeclampsi/eclampsia at our hospital ,first trimester whole blood count was taken and neutrophil lymphocyte ratio was calculated and recorded


Biospecimen Retention:   None Retained

whole blood, serum, white cells


Estimated Enrollment: 600
Study Start Date: May 2013
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
normal pregnancy outcomes
do not expect poor pregnancy outcomes on normal patients
Biological: high neutrophil to lymphocyte ratio Other: normal neutrophil-to Lymphocyte ratio
adverse pregnancy outcome
high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
Biological: high neutrophil to lymphocyte ratio Other: normal neutrophil-to Lymphocyte ratio

Detailed Description:

In recent years, have been reported that the individual components of the differential white cell count, specifically the neutrophil and lymphocyte counts, may have clinical utility in predicting diseases.

An elevated NLR has been shown to be a prognostic indicator in various malignancies. İn the literatüre have been shown that NLR have predictive value in determining the prognosis of various diseases (cardiac or noncardiac diseases.However, little is known about the predictive values of NLR and PLR in gestational DM, preeclampsia and the other pregnancy complications.

Retrospective data were collected for patients who was diagnosed with , preeclampsia- eclampsia, The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

first trimester pregnant

Criteria

Inclusion Criteria:

pregnant women who developing preeclampsia eclampsia at pregnancy

Exclusion Criteria:

Known chronically maternal disease multiple pregnancy older than 40 years old

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01856387

Locations
Turkey
Zekai Tahir Burak Maternity Teaching Hospital Recruiting
Ankara, Turkey
Contact: ayse kirbas    + 90 0 533 646 92 13    ayseozdemirkirbas@hotmail.com   
Contact: ali ersoy    + 90 312-306-5000      
Sub-Investigator: aliozgur ersoy         
Sponsors and Collaborators
Zekai Tahir Burak Women's Health Research and Education Hospital
Investigators
Principal Investigator: ayse kirbas Zekai Tahir Burak Women's Health Research and Education Hospital
  More Information

No publications provided

Responsible Party: Ayse Kirbas, Ayse Kirbas, MD, Zekai Tahir Burak Maternity and Teaching Hospital
ClinicalTrials.gov Identifier: NCT01856387     History of Changes
Other Study ID Numbers: Zekai Tahir Burak
Study First Received: May 4, 2013
Last Updated: March 16, 2014
Health Authority: Turkey: Ministry of Health

Keywords provided by Zekai Tahir Burak Women's Health Research and Education Hospital:
preeclampsia
eclampsia
prediction
neutrophil-to Lymphocyte ratio

Additional relevant MeSH terms:
Eclampsia
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on November 20, 2014